National Clinical Research Affiliations
Comprehensive Cancer Centers physicians are part of The US Oncology Network — one of the nation’s largest networks of community-based oncology physicians dedicated to advancing cancer care in America. The service provider offers more than 1,000 physicians nationwide who share in the development of clinical research, public policy initiatives and innovative cancer care advancements.
The following video from our partners at US Oncology Network shares more about how clinical research works. The video tells the story of people who make it all possible, including Comprehensive’s Dr. Nicholas Vogelzang, as well as patients whose lives have been saved through research.
Supported by McKesson Specialty Health and The US Oncology Network, US Oncology Research draws from a network of experienced investigators and dedicated clinical staff who specialize in Phase I through Phase IV oncology clinical trials. US Oncology Research serves approximately 60 research sites and nearly 170 locations managing about 225 active trials at any given time. Physicians in the research network have enrolled more than 60,000 patients in nearly 1,400 trials since inception in 1992 and have contributed to the development of 53cancer therapies approved by the FDA. For more information, click here.
Comprehensive Cancer Centers also partners with UCLA TRIO-US and leading pharmaceutical companies to offer groundbreaking research to its patients
Community Clinical Oncology Program
The Community Clinical Oncology Program (CCOP) was established by the National Cancer Institute (NCI) in 1983. Through this program, community physicians work with scientists conducting NCI-supported clinical trials. The CCOP introduces the newest clinical research findings and procedures to community settings. CCCN is affiliated with Nevada Cancer Research Foundation, which is a CCOP. Through this affiliation, CCCN oncologists are able to bring the latest cancer procedures and treatments to its patients.
In some cases, Comprehensive works with pharmaceutical companies independently to bring new treatments and novel therapies in cancer research to the community.